Pharmaco-proteomic Platform to Evaluate Drug Interactions in Liver Transplant Patients

The goal of this observational study is to enhance the ability to forecast kidney failure in liver transplant patients in the ICU under multidrug treatment by developing a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data. The main outcomes it aims to develop are:

1. Design the multidrug web computing platform with available information on drug pair interactions (DDIs). 2. Integrate the proteomic and clinical data of liver transplant patients into the IT platform. 3. Implement the multidrug web platform to predict the clinical evolution of liver transplant patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Drug-drug Interaction Liver Transplantation

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital ClínicoUC-Christus, Santiago, Santiago Metropolitan, Chile

About this study

The aim of this project is to enhance the ability to forecast kidney failure for liver transplant patients in the ICU by developing a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data. This integrated platform enables the prediction of the development of AKI in patients who have undergone OLT. Through the integration of mathematical models, the platform captures complex interactions between multiple drugs and proteomics data from patients, contributing to an improved predictive capacity for AKI outcomes.

By leveraging proteomic insights, personalized therapeutic interventions can be devised, promoting safer and more effective treatments. This research seeks to empower medical professionals with comprehensive information to navigate the complex landscape of drug interactions and personalized treatment strategies, ultimately contributing to improved patient outcomes and healthcare practices in the realm of liver transplantation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Liver transplant patients undergoing surgery at UC Christus Hospital

Exclusion criteria

Patients on renal replacement therapy
Patients for whom no clinical or pharmacological registry is available

Treatment and study plan

Multi-drug interaction

Other

The clinical impact associated with the use of multiple drugs in liver transplant patients during their stay in ICU will be evaluated.

Primary outcomes

Develop a web platform that combines information on interactions between multiple drugs and proteomic and clinical profiles, to predict the clinical evolution in liver transplant patients hospitalized in the ICU

Time frame: 18 to 24 months

Periodic developmental assessments will be carried out (Analysis of drug interaction graphs, Design of the interaction web platform, Integration of omics and clinical data into the web platform)

Study contacts

Contact information is provided by the study sponsor or research team.

Nelson Barrera, PhD

CONTACT

[email protected]

56987687058

Sponsors and collaborators

Lead sponsor

Pontificia Universidad Catolica de Chile

Other

Collaborators

Universidad Adolfo Ibañez
Universidad de Valparaiso

Registry information

Official study title

Development of a Pharmaco-proteomic Platform to Evaluate Potential Drug Interactions and Their Clinical Impact in Liver Transplant Patients Undergoing Multidrug Treatment

Important dates

Study start: 2023
Primary completion: 2024
Study completion: 2025
First posted: Nov 12, 2024
Registry last updated: Nov 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting